MAPK3 and acute lymphoblastic leukemia: When we analyzed expression of p-ERK1/2 as a marker for activation of the MEK/ERK pathway, we observed induction of p-ERK1/2 only in pevonedistat-treated ALL cells correlating with the significantly greater increased in intracellular Ca2+ observed in pevonedistat-treated ALL cells (Figure 2B).